Urine and Blood Drug Testing: Collection to Interpretation
THE OKOROCHA FIRM*
Content notice: Scientific and toxicology content on this site was written by non-toxicologist marketing staff at Connectica, LLC. It has not been verified for accuracy by a trained forensic toxicologist. Read the full Content Disclaimer.
Updated August 29, 2026. Urine and blood drug tests travel through a chain of collection, identification, transport, accession, analysis, review, and reporting. The reliability of the final interpretation depends on the records and controls at every stage.
Urine and blood answer different questions
Urine is commonly used to identify prior exposure to selected drugs or metabolites. It often provides a longer detection window than blood, but generally does not establish the exact time of use, dose, or impairment.
Blood is often selected when the concentration closer to an event matters, including some impaired-driving, clinical, and postmortem investigations. Interpretation still depends on collection time, specimen type, pharmacokinetics, tolerance, active metabolites, interactions, and case context. A blood concentration is not automatically proof of impairment or causation.
Step 1: define the testing purpose and scope
The requester and laboratory should identify the question being asked. A limited workplace panel, an emergency-department screen, an impaired-driving panel, and a postmortem toxicology examination do not test for the same compounds or use the same cutoffs. “Drug test” is not a complete description of analytical scope.
The test order, laboratory panel, target analytes, specimen type, screening method, confirmation method, cutoffs, and reporting rules should be documented. A drug outside the analytical scope cannot be excluded by a negative result.
Step 2: collect and identify the specimen
Collection requirements depend on the governing program and purpose. Federal workplace testing has detailed procedures that should not be assumed to govern every clinical, state, private, or court-ordered test.
Records should connect the donor or subject to the specimen through identifiers, date and time, collector documentation, container and seal information, and the requested analysis. For blood, relevant details can include the collection site, tube type, preservative or anticoagulant, number of tubes, fill volume, and time relative to the event. For urine, relevant details can include collection timing, seal identifiers, and specimen-validity measurements required by the applicable program.
Step 3: seal, transport, and store
The chain of custody should document possession and transfers from collection through final disposition. Gaps do not automatically prove contamination or substitution, but they can limit confidence and should be investigated.
Storage temperature, transit time, container material, preservative, light exposure, freeze-thaw history, and delays can matter for some analytes. The laboratory’s validated stability data and standard operating procedures should identify acceptable conditions.
Step 4: accession and specimen checks
At accession, the laboratory should compare identifiers, seals, requested tests, specimen type, volume, and condition. Any discrepancy, leakage, broken seal, insufficient quantity, or unsuitable specimen should be documented and addressed under laboratory policy.
Urine specimen-validity testing may include creatinine, specific gravity, pH, and testing for oxidants or adulterants, depending on the program. These measurements help assess whether the specimen meets defined validity criteria; they do not independently identify a drug.
Step 5: screening and confirmation
An initial immunoassay screen can rapidly classify a sample relative to a cutoff, but cross-reactivity and incomplete drug coverage make a positive screen presumptive. A negative screen applies only to the included targets, sensitivity, and cutoff.
When a result has significant consequences, an appropriate independent chemical method should identify the specific compound. Chromatography with mass spectrometry is commonly used for definitive testing. The method must be validated for its intended specimen and purpose.
Step 6: calibration, controls, and batch review
Analytical results should be evaluated with calibrators, blanks, positive and negative controls, internal standards, acceptance criteria, and review of potential interference or carryover. A number in a report is not sufficient to establish that the entire analytical batch met requirements.
ANSI/ASB Standard 036 addresses validation of forensic-toxicology methods. Validation helps demonstrate that a method is fit for its intended use through characteristics such as selectivity, sensitivity, calibration, accuracy, precision, carryover, stability, and matrix effects.
Step 7: technical and administrative review
Laboratories generally review analytical data, calculations, quality controls, identification criteria, and report language before release. The case file may also include reinjection or reanalysis records, dilution calculations, amended reports, peer-review notes, and communications about unusual findings.
Step 8: interpret only what the result supports
- A presumptive screen does not necessarily identify a specific compound.
- A confirmed urine result generally supports prior exposure, not exact timing, dose, or impairment.
- A blood concentration must be interpreted with collection time, pharmacology, tolerance, interactions, and method uncertainty.
- A negative result does not exclude drugs outside the panel or below the reporting limit.
- Detection does not automatically establish illegal use, prescription misuse, causation, or intent.
Records to obtain for a complete review
- Test order, analytical scope, panel, analytes, and cutoffs
- Collection forms, seal identifiers, and chain-of-custody records
- Transport, accession, storage, and specimen-condition records
- Specimen-validity results
- Screening and confirmation reports
- Method validation, standard operating procedures, and acceptance criteria
- Batch sequence, calibrators, controls, blanks, internal standards, and raw data
- Maintenance, quality-control, proficiency, and analyst qualification records
- Technical review, calculations, communications, and amended reports
Standards and primary sources
- Academy Standards Board. ANSI/ASB Standard 036: Standard Practices for Method Validation in Forensic Toxicology.
- Scientific Working Group for Forensic Toxicology. Standard practices for method validation in forensic toxicology. Journal of Analytical Toxicology. 2013;37(7):452-474. doi:10.1093/jat/bkt054.
- Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Therapeutic Drug Monitoring. 2004;26(2):200-205. doi:10.1097/00007691-200404000-00020.
- American College of Medical Toxicology. Interpretation of Urine Opiate and Opioid Tests. Journal of Medical Toxicology. 2022;18(2):176-179.
- Substance Abuse and Mental Health Services Administration. Federal workplace drug-testing resources.
Related reading: See Forensic Toxicology Testing: Specimens, Methods and Interpretation, Urine Drug Testing: Reliability, Detection Windows and Interpretation, Rapid Urine Drug Tests in Court: 12 Records That Matter, and the Forensic Toxicology topic hub.
This page is general informational and marketing content. It is not legal advice, expert opinion, or a statement of scientific fact. Case-specific interpretation requires the complete record and consultation with a qualified forensic toxicologist or licensed attorney.
